On Apr. 21, 2022, Cocrystal Pharma announced a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID) for exploratory preclinical studies to evaluate the potential of Cocrystal 3CL protease inhibitors for the treatment of COVID-19.

Cocrystal applied its proprietary drug discovery platform technology to develop novel, broad-spectrum SARS-CoV-2 3CL protease inhibitors. Under the NIAID collaboration, Cocrystal its 3CL protease inhibitors, and the NIAID was responsible for in vitro and in vivo studies evaluating the antiviral activity of the compounds.